Clinical Trials

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT02135042 2026-03-18

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT02193282 2026-03-18

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

390 enrolled

Phase NA Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02194738 2026-03-18

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

8,300 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03233711 2026-03-18

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

344 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT03244384 2026-03-18

AMBASSADOR

739 enrolled

Ureteral Neoplasms

NCT03811015 2026-03-18

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Oropharyngeal Neoplasms

NCT06498635 2026-03-18

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02954874 2026-03-17

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03055013 2026-03-17

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

819 enrolled 12 charts

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT07388524 2026-03-17

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

336 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05812807 2026-03-04

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

1,295 enrolled

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT05976763 2026-03-04

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

421 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

1,150 enrolled 6 charts

Dermatologic

Melanoma

NCT06647953 2026-02-24

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Phase 4 Not yet recruiting

110 enrolled

Pleuropulmonary blastoma

NCT07281547 2026-02-18

Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

25 enrolled

Gynecologic

Endometrial Neoplasms

NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

LymphoidOther hematologic neoplasm

120 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05333874 2026-02-09

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Phase EARLY_PHASE1 Active not recruiting

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06733350 2026-02-09

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Phase 4 Suspended

600 enrolled

Prostatic Neoplasms

NCT05633615 2026-02-02

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

396 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07370675 2026-01-27

Active Surveillance for Bethesda IV Thyroid Nodules

Phase NA Recruiting

165 enrolled

Phase 2/3 Active not recruiting

Thyroid Neoplasms, Thyroid Nodule

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

1 enrolled

Phase EARLY_PHASE1 Recruiting

Colonic Neoplasms

NCT07025226 2026-01-26

Senolytics

10 enrolled

Phase NA Active not recruiting

Glioma

NCT02914873 2026-01-20

PCASTT

2,008 enrolled

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07240220 2026-01-15

Merck-4

2,500 enrolled

Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

NCT03180268 2026-01-14

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

163 enrolled

Meningioma

NCT06378866 2025-12-26

DIVINE

532 enrolled

Prostatic Neoplasms

NCT03803553 2025-12-23

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

400 enrolled

Colonic Neoplasms

NCT02176967 2025-12-22

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

621 enrolled

Neuroblastoma, Ganglioneuroblastoma

NCT03533582 2025-12-22

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

537 enrolled

Fibrolamellar hepatocellular carcinoma, Hepatoblastoma

NCT02201992 2025-12-19

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

166 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01169337 2025-11-25

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Phase 2 Active not recruiting

226 enrolled 16 charts

Plasma cell

Smoldering Multiple Myeloma

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

95 enrolled

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT04519879 2025-10-29

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

133 enrolled

Prostatic Neoplasms

NCT01096368 2025-10-27

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

479 enrolled 24 charts

Ependymoma

NCT02882282 2025-10-23

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

Phase 2 Completed

15 enrolled 8 charts

Mouth Neoplasms

NCT03418961 2025-10-08

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

491 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Cardiotoxicity

NCT06200103 2025-09-11

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

236 enrolled

Prostatic Neoplasms

NCT02609685 2025-09-09

PMCAS

Phase NA Recruiting

216 enrolled

Papillary Thyroid Microcarcinoma, Thyroid Neoplasms

NCT06537154 2025-07-30

NEO-BLAST

Phase 2/3 Recruiting

688 enrolled

Urinary Bladder Neoplasms

NCT07023432 2025-06-17

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

78 enrolled

Carcinoma, Renal Cell

NCT06998342 2025-05-31

MOHSAHRTSS

24 enrolled

Head and Neck Neoplasms

NCT06861894 2025-05-15

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

164 enrolled

Esophageal Squamous Cell Carcinoma

NCT06974370 2025-05-15

ACTION-Brain

45 enrolled

Phase 2/3 Active not recruiting

Brain Neoplasms

NCT04068103 2025-05-07

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

635 enrolled 9 charts

Colonic Neoplasms

NCT06539468 2025-04-02

Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients

Phase NA Recruiting

200 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT06686381 2025-02-05

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

80 enrolled

Muscle-invasive Bladder Cancer

NCT02799745 2024-12-06

ENACT

Phase 2 Completed

227 enrolled 24 charts

Prostatic Neoplasms

NCT01725165 2024-10-24

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Phase 2 Completed

85 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT06238648 2024-09-26

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy